SUSMED,Inc. (JP:4263)
:4263
Top Page
SUSMED,Inc.
(4263)
Select Model
Select Model
Rating:52Neutral
Price Target:
¥972.00
▲(18.39% Upside)
Action:ReiteratedDate:04/09/26
The score is held back primarily by heavy ongoing losses and worsening cash burn despite strong gross margins, while the debt-free balance sheet provides stability. Technical signals are mixed (short-term weakness but longer-term support), and valuation remains pressured due to negative earnings and no dividend yield provided.
Positive Factors
High Gross Margins
SUSMED’s ~97% gross margins indicate exceptionally strong unit economics in its digital-health offerings. This structural margin cushion supports scalability and long-term profitability potential if operating expenses are reined in, enabling leverage as revenue grows.
Negative Factors
Deep Ongoing Losses
Persistent, large net losses indicate the company’s operating model has not yet converted strong unit economics into positive overall profits. Continued negative margins erode equity, require external funding over time, and reflect structural cost or scale challenges to delivering investor returns.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
SUSMED’s ~97% gross margins indicate exceptionally strong unit economics in its digital-health offerings. This structural margin cushion supports scalability and long-term profitability potential if operating expenses are reined in, enabling leverage as revenue grows.
Read all positive factors
SUSMED,Inc. (4263) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥15.99B
Dividend YieldN/A
Average Volume (3M)121.17K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue Growth39.30%
EPS Growth32.06%
CountryJP
Employees39
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding16,868,100
10 Day Avg. Volume117,240
30 Day Avg. Volume121,170
Financial Highlights & Ratios
PEG Ratio2.02
Price to Book (P/B)2.35
Price to Sales (P/S)22.16
P/FCF Ratio-23.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
SUSMED,Inc. Business Overview & Revenue Model
Company Description
SUSMED, Inc. develops and sells therapeutic applications in Japan. It develops smartphone based digital therapeutics applications for diseases with insomnia, breast cancer, and kidney disease. The company also develops and sells development platfo...
How the Company Makes Money
null...
SUSMED,Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
74
Positive
Cash Flow
28
Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 462.99M | 342.58M | 530.65M | 316.87M | 115.49M |
| Gross Profit | 450.72M | 330.85M | 522.67M | 306.50M | 105.73M |
| EBITDA | -291.50M | -358.99M | -42.77M | -227.10M | -333.31M |
| Net Income | -298.40M | -357.42M | -50.75M | -233.48M | -277.55M |
Balance Sheet | |||||
| Total Assets | 4.50B | 4.93B | 5.10B | 4.94B | 1.67B |
| Cash, Cash Equivalents and Short-Term Investments | 4.40B | 4.85B | 5.05B | 4.90B | 1.63B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 132.33M | 327.79M | 230.33M | 93.34M | 97.20M |
| Stockholders Equity | 4.37B | 4.60B | 4.87B | 4.85B | 1.58B |
Cash Flow | |||||
| Free Cash Flow | -436.79M | -240.04M | 82.40M | -177.90M | -239.49M |
| Operating Cash Flow | -432.48M | -230.76M | 100.59M | -165.28M | -235.09M |
| Investing Cash Flow | -19.97M | -8.53M | -18.19M | -20.36M | -4.40M |
| Financing Cash Flow | 3.67M | 37.37M | 62.36M | 3.46B | 1.50B |
SUSMED,Inc. Technical Analysis
Negative
821.00
Price Trends
996.96
Negative
949.47
Positive
877.04
Positive
Market Momentum
6.39
Negative
45.72
Neutral
60.12
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4263, the sentiment is Negative. The current price of 821 is below the 20-day moving average (MA) of 997.55, below the 50-day MA of 996.96, and below the 200-day MA of 877.04, indicating a neutral trend. The MACD of 6.39 indicates Negative momentum. The RSI at 45.72 is Neutral, neither overbought nor oversold. The STOCH value of 60.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4263.
SUSMED,Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | ¥1.12T | 18.91 | 12.15% | 1.01% | 33.50% | 17.26% | |
63 Neutral | ¥65.67B | 228.03 | ― | 0.39% | 6.17% | -8918.66% | |
63 Neutral | ¥233.94B | 26.76 | ― | 0.43% | 20.55% | 48.62% | |
52 Neutral | ¥15.99B | -23.39 | ― | ― | 39.30% | 32.06% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥69.14B | 77.03 | 5.76% | ― | 31.95% | -40.95% | |
44 Neutral | ¥2.79B | -4.28 | ― | ― | 16.19% | -4.42% |
* Healthcare Sector Average
JP:4263
SUSMED,Inc.
948.00
448.00
89.60%
JP:2413
M3
1,645.00
0.53
0.03%
JP:4480
Medley
2,112.00
-1,013.00
-32.42%
JP:3902
Medical Data Vision Co.Ltd.
1,684.00
1,292.00
329.59%
JP:4438
Welby Inc.
337.00
52.00
18.25%
JP:4483
JMDC Inc.
3,575.00
684.56
23.68%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.